B. Riley upgraded Kymera Therapeutics (KYMR) to Buy from Neutral with a price target of $60, up from $38. The company released the first-in-human data for KT-621, its oral STAT6 degrader, and it is “fair to say the program passed a key test,” not just in terms of target engagement, but, importantly, safety, the analyst tells investors in a research note. The firm says this was the main overhang for the stock heading into the update. The update “meaningfully de-risks” Kymera’s STAT6 program, and there are “no red flags” in the data, contends Riley. It believes KT-621 could become a best-in-class oral alternative to dupilumab, with potential to open up access for patients not currently on injectables. The firm sees additional share upside as the key investor program of interest is de-risked.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics’ KT-621 Shows Promising Potential, Upgraded to Overweight with $79 Target
- Kymera Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
- Kymera Therapeutics price target raised to $60 from $52 at Citi
- Kymera Therapeutics upgraded to Buy at BofA after KT-621 data
- Kymera Therapeutics upgraded to Buy from Neutral at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue